Categories Uncategorized

Understanding Prostate Cancer’s Early Warning Signs

Estimates show that nearly 200,000 Americans are diagnosed with prostate cancer annually, making it one of the most commonly diagnosed cancers after breast and lung cancer. The survival rate for this particular cancer is high, especially if diagnosed in its early stages. Figures show that when this cancer is diagnosed before it metastasizes, roughly 97% of individuals live at least five years after diagnosis.

However, most individuals with prostate cancer don’t display any symptoms or signs, especially when the disease is still in its early stages. This is why it’s important to know some of the signs of prostate cancer, because this will help you be on the lookout for any changes to your health.

Below are some of the signs that may indicate the presence of prostate cancer.

Burning or painful urination

This condition is referred to as dysuria and is commonly linked to urinary tract infections (“UTIs”). However, it may sometimes be a sign of prostate cancer.

The frequent need to urinate

The presence of a tumor on the prostate can apply pressure on an individual’s urethra and bladder. Therefore, if you feel the need to urinate frequently, particularly at night, you should visit your doctor.

Weak or slow urine flow

It is normal for individuals with prostates to have difficulty urinating as they age. It should be noted that it’s not usually because of prostate cancer. However, if your urine flow stops and starts uncontrollably, you should get your prostate examined.

Prostate pain

Experiencing pain in your prostate area, especially when sitting down, may be a sign of an infection. If you experience unexplained pain, visit your urologist for diagnosis.

Presence of blood in urine

This condition is also known as hematuria. While it may also indicate the presence of a UTI, you should still visit the doctor for a check-up. Avoid self-diagnoses.

Issues with ejaculation

If you find it hard to keep an erection, notice a reduced volume of ejaculation, experience painful ejaculations or have blood in your semen, you should visit a urologist for diagnosis. It should be noted, however, that ejaculation issues can also associated with other health conditions.

Doctors recommend that individuals get screened for prostate cancer as soon as they turn 40, especially if they have a high risk of developing the disease. In addition to this, you are advised to keep in mind that most of the symptoms mentioned above also show up as individuals age, hence the need to make use of some of the diagnostic technology availed by companies such as AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to get a definitive diagnosis of cancer.

NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

1 day ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

4 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago